Skip to main content
main-content
Erschienen in: Schmerzmedizin 3/2019

16.05.2019 | Migräne | DGS

Migräneprophylaxe

Erenumab — Empfehlungen für die Praxis

verfasst von: Prof. Dr. med. Dipl.-Psych. Hartmut Göbel, Dr. med. Axe Heinze, Dr. med. Katja Heinze-Kuhn, Dr. med. Astrid Gendolla, Dr. med. Johannes Horlemann

Erschienen in: Schmerzmedizin | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ernenumab ist der erste Antikörper, der zur Vorbeugung von Migräneattacken zugelassen wurde. Der folgende Artikel soll eine Übersicht darüber geben, welche Wirkung von Erneumab zu erwarten ist, für welche Patienten er geeignet und wie er in der Praxis anzuwenden ist.
Literatur
1.
Zurück zum Zitat Steiner TJ et al. Migraine: the seventh disabler. Cephalalgia 2013;33:289–90 CrossRef Steiner TJ et al. Migraine: the seventh disabler. Cephalalgia 2013;33:289–90 CrossRef
2.
Zurück zum Zitat Steiner TJ et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014;15:31 CrossRef Steiner TJ et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014;15:31 CrossRef
3.
Zurück zum Zitat Göbel H. Die Kopfschmerzen. 3. Ausgabe. Berlin, Heidelberg: Springer; 2012 CrossRef Göbel H. Die Kopfschmerzen. 3. Ausgabe. Berlin, Heidelberg: Springer; 2012 CrossRef
4.
Zurück zum Zitat Hagen K et al. Headache as a risk factor for dementia: a prospective population-based study. Cephalalgia 2014;34:327–35 CrossRef Hagen K et al. Headache as a risk factor for dementia: a prospective population-based study. Cephalalgia 2014;34:327–35 CrossRef
5.
Zurück zum Zitat GBD 2016 Disease and injury incidence and prevalence collaborators. global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211- 59 GBD 2016 Disease and injury incidence and prevalence collaborators. global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211- 59
6.
Zurück zum Zitat Steiner TJ et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 2018;19:17 CrossRef Steiner TJ et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 2018;19:17 CrossRef
7.
8.
Zurück zum Zitat Hu X et al. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci 2017;38:33–40 CrossRef Hu X et al. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci 2017;38:33–40 CrossRef
9.
Zurück zum Zitat Linde M et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012;19:703–11 CrossRef Linde M et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012;19:703–11 CrossRef
10.
Zurück zum Zitat Goadsby PJ et al. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev 2017;97:553–622 CrossRef Goadsby PJ et al. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev 2017;97:553–622 CrossRef
11.
Zurück zum Zitat Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol 2018;17:174–82 CrossRef Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol 2018;17:174–82 CrossRef
12.
Zurück zum Zitat Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache 2018;58:Suppl 1:4–16 CrossRef Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache 2018;58:Suppl 1:4–16 CrossRef
13.
Zurück zum Zitat Ong JJY et al. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs 2018;78:411–37 CrossRef Ong JJY et al. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs 2018;78:411–37 CrossRef
14.
Zurück zum Zitat Ashina H et al. CGRP in human models of migraine. Handb Exp Pharmacol. online 13. Juni 2018 doi:10.1007/164_2018_128 Ashina H et al. CGRP in human models of migraine. Handb Exp Pharmacol. online 13. Juni 2018 doi:10.1007/164_2018_128
15.
Zurück zum Zitat Edvinsson L (2018) The CGRP pathway in migraine as a viable target for therapies. Headache 58 Suppl 1:33–47 CrossRef Edvinsson L (2018) The CGRP pathway in migraine as a viable target for therapies. Headache 58 Suppl 1:33–47 CrossRef
16.
Zurück zum Zitat Edvinsson L et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 2018;14:338–50 CrossRef Edvinsson L et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 2018;14:338–50 CrossRef
17.
Zurück zum Zitat Holland PR. Foreword: The CGRP pathway and migraine prevention: reducing the burden of disease. Headache 2018;58 Suppl 1:1–3 CrossRef Holland PR. Foreword: The CGRP pathway and migraine prevention: reducing the burden of disease. Headache 2018;58 Suppl 1:1–3 CrossRef
18.
Zurück zum Zitat Maasumi K et al. CGRP and migraine: The role of blocking Calcitonin Gene-Related Peptide ligand and receptor in the management of migraine. Drugs 2018;78:913–28 CrossRef Maasumi K et al. CGRP and migraine: The role of blocking Calcitonin Gene-Related Peptide ligand and receptor in the management of migraine. Drugs 2018;78:913–28 CrossRef
19.
Zurück zum Zitat Messina R et al. CGRP - a target for acute therapy in migraine: Clinical data. Cephalalgia 2019;39:420–7 CrossRef Messina R et al. CGRP - a target for acute therapy in migraine: Clinical data. Cephalalgia 2019;39:420–7 CrossRef
20.
Zurück zum Zitat Cauchi M et al. CGRP and migraine. J Neurol 2016;263:192–4 Cauchi M et al. CGRP and migraine. J Neurol 2016;263:192–4
21.
Zurück zum Zitat Deen M et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 2017;18:96 doi:10.1186/ s10194-017-0807-1 CrossRef Deen M et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 2017;18:96 doi:10.1186/ s10194-017-0807-1 CrossRef
22.
Zurück zum Zitat Edvinsson L. The journey to establish CGRP as a migraine target: A retrospective view. Headache 2015;55:1249–55 CrossRef Edvinsson L. The journey to establish CGRP as a migraine target: A retrospective view. Headache 2015;55:1249–55 CrossRef
23.
Zurück zum Zitat Fiala JL et al. Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape. Nat Rev Drug Discov 2016;15:8–9 CrossRef Fiala JL et al. Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape. Nat Rev Drug Discov 2016;15:8–9 CrossRef
24.
Zurück zum Zitat Karsan N et al. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 2015;15:25 CrossRef Karsan N et al. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 2015;15:25 CrossRef
25.
Zurück zum Zitat Khan S et al. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia 2019;39:374–89 CrossRef Khan S et al. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia 2019;39:374–89 CrossRef
26.
Zurück zum Zitat Wrobel Goldberg S et al. Targeting CGRP: A new era for migraine treatment. CNS Drugs 2015;29:443–52 CrossRef Wrobel Goldberg S et al. Targeting CGRP: A new era for migraine treatment. CNS Drugs 2015;29:443–52 CrossRef
27.
Zurück zum Zitat Yuan H et al. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs 2017;31:487–501 CrossRef Yuan H et al. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs 2017;31:487–501 CrossRef
28.
Zurück zum Zitat Tepper SJ History and review of anti- Calcitonin Gene-Related Peptide (CGRP) therapies: From translational research to treatment. Headache 2018;58:Suppl 3:238–75 CrossRef Tepper SJ History and review of anti- Calcitonin Gene-Related Peptide (CGRP) therapies: From translational research to treatment. Headache 2018;58:Suppl 3:238–75 CrossRef
29.
Zurück zum Zitat Shi L et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther 2016;356:223–31 CrossRef Shi L et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther 2016;356:223–31 CrossRef
30.
Zurück zum Zitat Goadsby PJ et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990:28:183–7 CrossRef Goadsby PJ et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990:28:183–7 CrossRef
31.
Zurück zum Zitat Cernuda-Morollon E et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013;81:1191–6 CrossRef Cernuda-Morollon E et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013;81:1191–6 CrossRef
32.
Zurück zum Zitat Lassen LH et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54–61 CrossRef Lassen LH et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54–61 CrossRef
33.
Zurück zum Zitat Goadsby PJ et al. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48–56 CrossRef Goadsby PJ et al. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48–56 CrossRef
34.
Zurück zum Zitat Olesen J et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104–10 CrossRef Olesen J et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104–10 CrossRef
35.
Zurück zum Zitat Ho TW et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014;83:958–66 CrossRef Ho TW et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014;83:958–66 CrossRef
36.
Zurück zum Zitat Goadsby PJ et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med 2017;377:2123–32 CrossRef Goadsby PJ et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med 2017;377:2123–32 CrossRef
37.
Zurück zum Zitat Tepper S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, doubleblind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16:425–34 CrossRef Tepper S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, doubleblind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16:425–34 CrossRef
38.
Zurück zum Zitat Reuter U et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebocontrolled, phase 3b study. Lancet 2018;392:2280–7 CrossRef Reuter U et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebocontrolled, phase 3b study. Lancet 2018;392:2280–7 CrossRef
40.
Zurück zum Zitat Depre C et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of Erenumab on exercise time during a treadmill test in patients with stable angina. Headache 2018;58:715–23 CrossRef Depre C et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of Erenumab on exercise time during a treadmill test in patients with stable angina. Headache 2018;58:715–23 CrossRef
41.
Zurück zum Zitat Göbel H et al. Gesundheitsverhalten von Migräne- und Kopfschmerzpatienten bei digitaler Therapiebegleitung mit der Migräne-App. Schmerz 2019;33:147–55 CrossRef Göbel H et al. Gesundheitsverhalten von Migräne- und Kopfschmerzpatienten bei digitaler Therapiebegleitung mit der Migräne-App. Schmerz 2019;33:147–55 CrossRef
42.
Zurück zum Zitat Schwedt T et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 2018;19:92 CrossRef Schwedt T et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 2018;19:92 CrossRef
43.
Zurück zum Zitat Ashina M et al. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology 2017;89:1237–43 CrossRef Ashina M et al. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology 2017;89:1237–43 CrossRef
45.
Zurück zum Zitat Diener HC et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie 2018. In: Deutsche Gesellschaft für Neurologie (Hrsg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.​dgn.​org/​leitlinien Diener HC et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie 2018. In: Deutsche Gesellschaft für Neurologie (Hrsg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.​dgn.​org/​leitlinien
46.
Zurück zum Zitat Göbel H et al. Chronic migraine and headache by medication overuse. Evolution and revision of classification. Schmerz 2011;25:493–500 CrossRef Göbel H et al. Chronic migraine and headache by medication overuse. Evolution and revision of classification. Schmerz 2011;25:493–500 CrossRef
Metadaten
Titel
Migräneprophylaxe
Erenumab — Empfehlungen für die Praxis
verfasst von
Prof. Dr. med. Dipl.-Psych. Hartmut Göbel
Dr. med. Axe Heinze
Dr. med. Katja Heinze-Kuhn
Dr. med. Astrid Gendolla
Dr. med. Johannes Horlemann
Publikationsdatum
16.05.2019
Verlag
Springer Medizin
Erschienen in
Schmerzmedizin / Ausgabe 3/2019
Print ISSN: 2194-2536
Elektronische ISSN: 2364-1010
DOI
https://doi.org/10.1007/s00940-019-1071-z